Completed NA INTERVENTIONAL 2-arm NCT00194896

Preferred Treatment of Type 1.5 Diabetes

Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes

Sponsor: GlaxoSmithKline

Updated 9 times since 2017 Last updated: Mar 27, 2018 Started: Feb 29, 2000 Primary completion: Sep 30, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed NA
Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Seattle Institute for Biomedical and Clinical Research
University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States